Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer

被引：0
|
作者：
Ni, M. [1 ]
Zhou, L. [1 ]
Lu, Y. [2 ]
Zhang, L. [2 ,3 ]
Li, X. [4 ]
Chen, M. [2 ]
Yang, A. [5 ]
Zhang, L. [2 ,3 ]
Xu, F. [1 ]
Yuan, Z. [1 ]
Wang, S. [1 ]
Shi, Y. [1 ]
An, X. [5 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Tumor Hosp, Guangxi, Peoples R China
[3] Puning Peoples Hosp, Puning, Peoples R China
[4] Guangzhou Panyu Cent Hosp, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Breast Oncol, Ctr Canc, Collaborat Innovat Ctr Canc Med,State Key Lab Onc, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.198
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
63P
引用
收藏
页码：S1490 / S1490
页数：1
相关论文
共 50 条
  • [1] Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
    Mengqian Ni
    Lijia Zhou
    Yongkui Lu
    Dachuan Guo
    Xiuyue Li
    Lixia Li
    Lidong Zhang
    Meiting Chen
    Lulu Zhang
    Fei Xu
    Zhongyu Yuan
    Shusen Wang
    Yanxia Shi
    Anli Yang
    Xin An
    [J]. BMC Cancer, 24 (1)
  • [2] EFFICACY AND SAFETY OF ERIBULIN IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER: REAL LIFE EXPERIENCE
    Zhilyaeva, Larisa
    [J]. BREAST, 2017, 36 : S53 - S54
  • [3] Safety and efficacy of eribulin as second-line treatment for HER2-negative metastatic breast cancer.
    Michalaki, Vasiliki
    Psychogios, John
    Contis, John
    Kondi, Agathi
    Gennatas, Constantine
    Papadimitriou, Christos A.
    Vasiliou, John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] The Efficacy of Eribulin Monotherapy after Anthracycline and Taxane in HER2-Negative Metastatic Breast Cancer
    Tsushita, Natsuko
    Shimoi, Tatsunori
    Kitano, Atsuko
    Shimomura, Akihiko
    Kodaira, Makoto
    Yunokawa, Mayu
    Yonemori, Kan
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Tamura, Kenji
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] SAFETY AND EFFICACY OF MAINTENANCE BEVACIZUMAB IN HER2-NEGATIVE METASTATIC BREAST CANCER
    Russillo, M.
    Metro, G.
    Giannarelli, D.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Cognetti, F.
    Fabi, A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 105 - 105
  • [6] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
    Hardy-Bessard, Anne-Claire
    Brocard, Fabien
    Clatot, Florian
    Lortholary, Alain
    You, Benoit
    Grenier, Julien
    Martin-Babau, Jerome
    Lucas, Brigitte
    Meunier, Jerome
    Ferrero, Jean-Marc
    Savoye, Aude-Marie
    Marti, Adina
    Despax, Raymond
    Moullet, Isabelle
    Emile, George
    [J]. BREAST, 2020, 54 : 256 - 263
  • [7] A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer
    Tsushita, N.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Kitano, A.
    Nishikawa, T.
    Shimomura, A.
    Noguchi, E.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer.
    Landry, Chrystal Ann
    Guziel, Jeannette Marcelle
    Ru, Meng
    Shapiro, Charles L.
    Fasano, Julie
    Bhardwaj, Aarti Sonia
    Irie, Hanna
    Bhardwaj, Nina
    Tiersten, Amy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
    Shingaki, Sumito
    Kogawa, Takahiro
    Shimokawa, Mototsugu
    Haranol, Kenichi
    Naito, Yoichi
    Kusuharal, Shota
    Fujimoto, Yumi
    Matsubaral, Nobuaki
    Hosono, Ako
    Mukail, Hirofumi
    Onishi, Tatsuya
    Hojo, Takashi
    Mukohara, Toru
    [J]. JOURNAL OF CANCER, 2020, 11 (14): : 4099 - 4105
  • [10] Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
    Milana Bergamino Sirvén
    Adela Fernández-Ortega
    Agostina Stradella
    Idoia Morilla
    Catalina Falo
    Silvia Vázquez
    Roser Castany
    Rafael Villanueva
    Sabela Recalde
    Valentí Navarro Pérez
    Miguel Gil-Gil
    Sonia Pernas
    [J]. BMC Pharmacology and Toxicology, 20
12345